{"groups":[{"description":"Fulvestrant 250 mg Intramuscular Injection every 28 days","id":"FG000","title":"Fulvestrant 250 mg"},{"description":"Fulvestrant 500 mg Intramuscular Injection every 28 days plus 500 mg on day 14","id":"FG001","title":"Fulvestrant 500 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"33"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"293"},{"groupId":"FG001","numSubjects":"261"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"10"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"37"},{"groupId":"FG001","numSubjects":"45"}],"type":"Ongoing in FU but not on treatment"}],"milestones":[{"achievements":[{"comment":"randomised patients","groupId":"FG000","numSubjects":"374"},{"comment":"randomised patients","groupId":"FG001","numSubjects":"362"}],"type":"STARTED"},{"achievements":[{"comment":"ongoing study treatment at survival follow-up data cut-off","groupId":"FG000","numSubjects":"8"},{"comment":"ongoing study treatment at survival follow-up data cut-off","groupId":"FG001","numSubjects":"13"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"366"},{"groupId":"FG001","numSubjects":"349"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}